Developing Phytoestrogens for Breast Cancer Prevention

Author(s): Mandy M. Liu, Ying Huang, Jeffrey Wang

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 12 , Issue 10 , 2012

Become EABM
Become Reviewer
Call for Editor


Breast cancer is one of the most common types of cancer in women, and is the second leading cause of cancer-related deaths in the United States. Chemoprevention using phytoestrogens (PEs) for breast cancer may be a valid strategy. PEs are phytochemicals with estrogen-like structures and can be classified into four types: isoflavones, lignans, stilbenes and coumestans. They are widely distributed in diet and herbs and have shown anti-cancer activity via mechanisms including estrogen receptor modulation, aromatase inhibition, and anti-angiogenesis. Genistein, daidzein and resveratrol are some of the most studied PE examples. Quality control in product manufacturing and clinical study design is a critical issue in developing them as clinically effective chemopreventive agents for breast cancer.

Keywords: Phytoestrogens, Breast cancer, Chemoprevention, Estrogen receptor modulator, Aromatase inhibitor, Genistein, Daidzein, Glycitein, Equol, Matairesinol, Secoisolariciresinol, Sesamin, Enterolactone, Enterodiol, Resveratrol, Coumestrol

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 05 November, 2012
Page: [1306 - 1313]
Pages: 8
DOI: 10.2174/187152012803833062
Price: $65

Article Metrics

PDF: 33